Randomized phase III trial in extended stage small cell lung cancer comparing first line platinum in combination with etoposide or topotecan

Click to increase image sizeClick to decrease image size

Author contribution

All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Morten Mau-Sørensen, Jonas Gerner-Rasmussen, Olfred Hansen, and Seppo W. Langer. The first draft of the manuscript was written by Morten Mau-Sørensen, Jonas Gerner-Rasmussen, and Seppo W. Langer, and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.

Data availability statement

Data available on request from the authors.

Disclosure statement

SWL: Advisory board, research collaboration, speaker fee: Roche, Merck, Amgen, AbbVie, Jannsen Pharma, Boehringer-Ingelheim.

Ethics approval

The study protocol was approved by a national ethics committee. Written informed consent was required, and the study was conducted in accordance with the declaration of Helsinki. The study was registered in ClinicalTrials.gov, NCT 00812266.

Additional information

Funding

The conduction of the study was supported by an unrestricted grant from Glaxo-Smith-Kline

The conduction of the study was supported by an unrestricted grant from Glaxo-Smith-Kline.